Immunogen Inc. announced Wednesday that it has filed aregistration statement with the Securities and ExchangeCommission for a public offering of 2.5 million shares ofcommon stock.

The offering is the company's first since 1991, when it filedtwo follow-on offerings of 2 million shares each, one at $19 pershare and the other at $17 per share. Immunogen filed itsinitial public offering of 1.5 million shares at $10 per share inNovember 1989.

The underwriters for the current offering are Smith BarneyShearson Inc. and Montgomery Securities.

Immunogen (NASDAQ:IMGN) of Cambridge, Mass., has fourproducts in clinical trials. Its lead compound, Oncolysin B, is inPhase III trials for treatment of non-Hodgkin's lymphoma andacute lymphocytic leukemia. Additional clinical trials are underway for its use in chronic lymphocytic leukemia, AIDSlymphoma and ex vivo bone marrow purging.

Oncolysin M is in clinicals for bone marrow purging in acutemyelogenous leukemia, Oncolysin S for small-cell lung cancer,and Oncolysin CD6 for T cell malignancies and acute organtransplant rejection.

Immunogen reported a net loss of $4.9 million for its firstquarter of fiscal 1994 ended Sept. 30.

Immunogen's stock closed at $10.38 a share on Wednesday, up25 cents. -- Brenda Sandburg

(c) 1997 American Health Consultants. All rights reserved.